Regulatory T Cell Interventions to Boost Anti-tumor Immune Responses.

FOXP3-expressing regulatory T cells in the tumor microenvironment are a major barrier to anti-tumor immunity, limiting cancer immunotherapy efficacy.

• Why it matters: Their immunosuppressive activity and widespread presence in tumors hinder immune escape, creating a key challenge for improving outcomes with cancer immunotherapy.
• What they did: This review surveys therapeutic ways to modulate Tregs, including antibody-based targeting, small-molecule inhibitors, engineered Tregs, microbiome modulation, and Treg survival manipulations, plus combination regimens.
• The result: Treg-targeted interventions are highlighted as a route to overcome immune escape and enhance immunotherapy efficacy, with the aim of improving clinical outcomes in cancer patients.

AI summary of the abstract · may contain errors · not medical advice · read the paper.